Rubicon Research

Q: Why is Rubicon Research Ltd falling/rising?

As of 08-Aug, Rubicon Research Ltd's stock price is rising, currently at 1,555.25, reflecting an increase of 22.2 points or 1.45%. This upward movement is supported by several positive factors. Over the past week, the stock has risen by 4.20%, significantly outperforming the Sensex, which only increased by 0.52%. In the past month, the stock has shown a robust gain of 12.56%, while the Sensex has only risen by 0.41%. Year-to-date, Rubicon Research has achieved an impressive increase of 129.46%, contrasting sharply with the Sensex's decline of 7.89%.Today's performance indicates that the stock is close to its 52-week high, being just 1.94% away from the peak of Rs 1589. The stock reached an intraday high of Rs 1572, marking a 2.54% increase during the trading day. Additionally, Rubicon Research is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is often seen as a bullish indicator.Investor participation has also risen, with delivery volume increasing by 71.65% compared to the 5-day average, indicating growing interest among retail investors. The stock's liquidity is sufficient for trading, with a value of Rs 0.56 crore based on 2% of the 5-day average traded value.Despite some concerns regarding institutional investor participation, which has decreased by 0.6% in the previous quarter, the overall strong performance metrics, including a significant growth in net profit of 88.33% and a solid ability to service debt, contribute to the stock's positive momentum. Thus, the combination of strong returns, rising investor interest, and favorable trading conditions are driving the stock price of Rubicon Research Ltd higher.

Q: What does Rubicon Research do?

Overview: Rubicon Research Ltd is a company operating in the Pharmaceuticals & Biotechnology industry within the Small Cap market-cap bracket.History: Rubicon Research Limited was incorporated on May 6, 1999, originally as Rubicon Consultants Private Limited. The company later changed its name to Rubicon Research Private Limited, receiving a fresh Certificate of Incorporation on September 2, 2002. The latest quarterly results reported net sales and net profit for the period ending March 2026.Financial Snapshot: Most recent Net Sales: 514 Cr (Quarterly Results - Mar 2026) Most recent Net Profit: 77 Cr (Quarterly Results - Mar 2026) Market-cap value: INR 19,408 Cr (Small Cap)Key Metrics: P/E: 80.00 Industry P/E: 34 Dividend Yield: 0.00% Debt-Equity: -0.03 Return on Equity: 19.14% Price to Book: 14.97Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Who are the peers of the Rubicon Research?

Peers: The peers of Rubicon Research are Neuland Labs., Piramal Pharma, Astrazeneca Phar, Pfizer, ERIS Lifescience, OneSource Speci., Granules India, Caplin Point Lab, Cohance Life, and Natco Pharma.Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Neuland Labs., Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, and Natco Pharma, and Average management risk is noted at Cohance Life, while Below Average management risk is present at OneSource Speci. and Piramal Pharma. Growth is Excellent at OneSource Speci., Good at Neuland Labs., Piramal Pharma, and Granules India, while Below Average growth is seen at Astrazeneca Phar, Pfizer, ERIS Lifescience, Caplin Point Lab, Cohance Life, and Natco Pharma. For Capital Structure, Excellent ratings are given to Neuland Labs., Astrazeneca Phar, Pfizer, Granules India, Caplin Point Lab, and Cohance Life, while Good is noted for ERIS Lifescience, and Below Average is seen at Piramal Pharma and OneSource Speci.Return Snapshot: Granules India has the highest 1-year return at 44.87%, while Piramal Pharma has the lowest at -20.05%, with Rubicon Research's 1-year return being N/A. Additionally, peers with negative six-month returns include ERIS Lifescience, OneSource Speci., Cohance Life, and Piramal Pharma.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE506V01022
NSEID: RUBICON
BSEID: 544578
View on NSE | View on BSE

INR

1,555.25

22.2 (1.45%)

BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 1.03 lacs

Access older stock analysis version

Dividend Alert: Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.03 lacs (-40.90%) Volume

Shareholding (Jun 2026)

FII

7.52%

Held by 39 FIIs

DII

9.43%

Held by 11 DIIs

Promoter

59.76%

Why is Rubicon Research Ltd falling/rising?

09-Aug-2026

As of 08-Aug, Rubicon Research Ltd's stock price is rising to 1,555.25, up 1.45%, supported by strong performance metrics and increased investor interest. The stock has gained 129.46% year-to-date and is nearing its 52-week high, indicating bullish trading conditions.

View full answer

Which are the latest news on Rubicon Research?

09-Aug-2026

Rubicon Research Ltd is Rated Strong Buy
Rubicon Research Ltd Technical Momentum Shifts Signal Strong Buy Outlook

What does Rubicon Research do?

11-Jun-2026

Rubicon Research Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 514 Cr and a net profit of 77 Cr for the quarter ending March 2026. It has a market cap of INR 19,408 Cr, a P/E ratio of 80.00, and a return on equity of 19.14%.

View full answer

How big is Rubicon Research?

11-Jun-2026

As of 10th June, Rubicon Research Ltd has a market capitalization of 19,408.00 Cr, with recent Net Sales of 1,753.96 Cr and a Net Profit of 246.74 Cr.

View full answer

Who are the peers of the Rubicon Research?

11-Jun-2026

Rubicon Research's peers include Neuland Labs, Piramal Pharma, Astrazeneca Pharma, Pfizer, ERIS Lifescience, Granules India, Caplin Point Lab, Cohance Life, OneSource Specialty, and Natco Pharma, with varying management risk and growth ratings. Granules India leads in 1-year returns at 44.87%, while Piramal Pharma has the lowest at -20.05%.

View full answer

Should I buy, sell or hold Rubicon Research Ltd?

03-Jun-2026

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

View full answer

Compare Rubicon Research with Similar Stocks

Acutaas Chemical Neuland Labs.Piramal Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

With a growth in Net Profit of 88.33%, the company declared Outstanding results in Mar 26

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 25,773 Cr (Small Cap)

P/E

105.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

19.14%

Price to Book

19.70

Revenue and Profits:

Net Sales:

514 Cr

(Quarterly Results - Mar 2026)

Net Profit:

77 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

63.38%

0.16%

63.54%

6 Months

98.2%

0.19%

98.39%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Latest dividend: 1.4980944625407164 per share ex-dividend date: Aug-07-2026

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Rubicon Research Ltd is Rated Strong Buy

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 07 August 2026, providing investors with the most up-to-date insight into the stock’s performance and prospects.

Read full news article

Rubicon Research Ltd Technical Momentum Shifts Signal Strong Buy Outlook

Rubicon Research Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, prompting an upgrade to a Strong Buy rating with a robust Mojo Score of 82.0. Recent technical indicators reveal a transition from bullish to mildly bullish trends, signalling potential upside for investors amid a backdrop of impressive year-to-date returns of 121.6% compared to the Sensex’s negative 7.7%.

Read full news article

Rubicon Research Ltd Falls 1.74%: 4 Key Factors Driving the Weekly Decline

Key Events This Week

27 Jul: New 52-week and all-time high at Rs.1,558.90

28 Jul: Further 52-week high at Rs.1,589 despite slight price dip

30 Jul: Notable price decline of 2.20% amid volume increase

31 Jul: Week closes at Rs.1,492.60, down 0.21% on the day

Read full news article

Announcements

Earnings Conference Call

07-Aug-2026 | Source : BSE

Earnings Conference Call

Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026

07-Aug-2026 | Source : BSE

Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve The Un-Audited Standalone and Consolidated financial results of the Company for the quarter ended June 30 2026.

Announcement under Regulation 30 (LODR)-Newspaper Publication

04-Aug-2026 | Source : BSE

Newspaper Advertisment titled Notice of the 27th Annual General Meeting and voting Information

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.10

Debt to EBITDA (avg)

1.50

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.16

Tax Ratio

23.02%

Dividend Payout Ratio

0.23%

Pledged Shares

Institutional Holding

16.95%

ROCE (avg)

25.58%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

105

Industry P/E

Price to Book Value

20.02

EV to EBIT

72.59

EV to EBITDA

64.38

EV to Capital Employed

20.55

EV to Sales

14.69

PEG Ratio

Dividend Yield

0.10%

ROCE (Latest)

28.31%

ROE (Latest)

19.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (7.23%)

FIIs

Held by 39 FIIs (7.52%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.83%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.52%)

Individual Investors Holdings

3.46%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "389.88",
          "val2": "301.71",
          "chgp": "29.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.17",
          "val2": "62.24",
          "chgp": "70.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.51",
          "chgp": "-28.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "70.02",
          "val2": "37.18",
          "chgp": "88.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.23%",
          "val2": "20.63%",
          "chgp": "6.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

389.88

301.71

29.22%

Operating Profit (PBDIT) excl Other Income

106.17

62.24

70.58%

Interest

5.40

7.51

-28.10%

Exceptional Items

0.00

Standalone Net Profit

70.02

37.18

88.33%

Operating Profit Margin (Excl OI)

27.23%

20.63%

6.60%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

614.49

528.16

16.35%

Operating Profit (PBDIT) excl Other Income

142.24

144.68

-1.69%

Interest

18.06

16.26

11.07%

Exceptional Items

0.00

Standalone Net Profit

80.96

89.04

-9.07%

Operating Profit Margin (Excl OI)

23.15%

27.39%

-4.24%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

916.20

773.03

18.52%

Operating Profit (PBDIT) excl Other Income

204.48

208.58

-1.97%

Interest

25.57

23.51

8.76%

Exceptional Items

0.00

Standalone Net Profit

118.14

127.27

-7.17%

Operating Profit Margin (Excl OI)

22.32%

26.98%

-4.66%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1,753.96

1,284.27

36.57%

Operating Profit (PBDIT) excl Other Income

400.24

264.26

51.46%

Interest

42.17

36.78

14.65%

Exceptional Items

0.00

Consolidate Net Profit

246.74

134.36

83.64%

Operating Profit Margin (Excl OI)

22.82%

20.58%

2.24%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

All Annual Results

Company CV

About Rubicon Research Ltd

Rubicon Research Ltd

Small Cap

Pharmaceuticals & Biotechnology

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.

Company Coordinates

No Company Details Available